[tmandry]

Study design: Tracks 200 people over one year and measures a suite of biomarkers at the beginning, 6 months, and 12 months. Participants are randomly assigned to one of four dosages or a placebo. Double blind.

The study hopes to find an optimal dose for humans using the various biomarkers as a guide. I’m not sure how well we can connect those biomarkers to actual longevity/healthspan.

Source: https://www.lifespan.io/news/a-campaign-to-launch-rapamycin-...

[Gatsky]

Realistically you have to start with something like this before doing a huge 30 year study (with potentially the wrong dose).